Greenpeace's latest report on biotechnology may be welcomed by those already inclined against biotech but it will be scoffed at by those already using it. GIs versus Biologics Powerful Senate Finance Committee Chairman Orrin Hatch (R-Utah) is angry that U.S. invented biologic drugs receive just five years of intellectual property protection under the TPP, and he is in a position to greatly frustrate ratification of the agreement in Congress. The treatment of biologics in TPP raises a broader question: why does the intellectual property value of American invented pharmaceuticals only receive five years of protection under the TPP but, if the EU’s demand in TTIP is agreed, food identified by its historic name would obtain permanent exclusiv...
Weighing in on strategic realignment
WPI’s team was retained by the governing board of a U.S. industry organization to review a decision, reached by vote, to invest significant assets into the development and management of an export trading company. WPI’s team conducted a formal review of this decision and concluded that the current level of market saturation would limit the benefits of the investment. Based on WPI’s analysis and recommended actions, the board subsequently reversed its decision and undertook a strategic planning effort to identify more impactful investments. On behalf of numerous clients, WPI has not only assisted in identifying strategic paths but also advised their implementation.